Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response
机构:[1]Department of Neurosurgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, China.[2]Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.[3]Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China.[4]Department of Outpatient, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, China.[5]Department of Neurosurgery, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi, China.[6]Department of Neurosurgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, Guangdong Province, China.
Epigenetic regulations of immune responses are essential for cancer development and growth. As a critical step, comprehensive and rigorous explorations of m6A methylation are important to determine its prognostic significance, tumor microenvironment (TME) infiltration characteristics and underlying relationship with glioblastoma (GBM).To evaluate m6A modification patterns in GBM, we conducted unsupervised clustering to determine the expression levels of GBM-related m6A regulatory factors and performed differential analysis to obtain m6A-related genes. Consistent clustering was used to generate m6A regulators cluster A and B. Machine learning algorithms were implemented for identifying TME features and predicting the response of GBM patients receiving immunotherapy.It is found that the m6A regulatory factor significantly regulates the mutation of GBM and TME. Based on Europe, America, and China data, we established m6Ascore through the m6A model. The model accurately predicted the results of 1206 GBM patients from the discovery cohort. Additionally, a high m6A score was associated with poor prognoses. Significant TME features were found among the different m6A score groups, which demonstrated positive correlations with biological functions (i.e., EMT2) and immune checkpoints.m6A modification was important to characterize the tumorigenesis and TME infiltration in GBM. The m6Ascore provided GBM patients with valuable and accurate prognosis and prediction of clinical response to various treatment modalities, which could be useful to guide patient treatments.
基金:
This study was supported by grants from: 1. 2020
Guangxi Zhuang Autonomous Region Health Committee
self-funded scientific research project, project number
20201558, 2. In 2020, the general project of high-level
talent scientific research project of the Affiliated Hospital of Youjiang Medical College for Nationalities (the young
and middle-aged backbone talent project), contract
number Y202011702, 3. 2021 Guangxi University’s
young and middle-aged teachers’ basic research ability
improvement project, project number 2021KY0542.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|2 区医学
小类|3 区老年医学3 区细胞生物学
最新[2025]版:
无
第一作者:
第一作者机构:[1]Department of Neurosurgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Li Chuanyu,Liu Wangrui,Liu Chengming,et al.Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response[J].Aging.2023,15:doi:10.18632/aging.204495.
APA:
Li Chuanyu,Liu Wangrui,Liu Chengming,Luo Qisheng,Luo Kunxiang...&Wang Xiangyu.(2023).Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response.Aging,15,
MLA:
Li Chuanyu,et al."Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response".Aging 15.(2023)